World Journal of Biology Pharmacy and Health Sciences
eISSN: 2582-5542
Cross Ref DOI: 10.30574/wjbphs
Journal homepage: https://wjbphs.com/

(REVIEW ARTICLE)

Check for updates

Application of pharmacometric approaches in diabetes mellitus

Divyaprasath. P *, Lakshmi Priyanka. P and Harineshwari. V

Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tiruchengode, Tamilnadu – 637205, India.

World Journal of Biology Pharmacy and Health Sciences, 2024, 19(03), 453–457

Publication history: Received on 29 July 2024; revised on 16 September 2024; accepted on 19 September 2024

Article DOI: https://doi.org/10.30574/wjbphs.2024.19.3.0645

Abstract

Pharmacometrics is a scientific field which employs statistical and mathematical techniques to analyse, comprehend, and estimate a drug's pharmacokinetics and pharmacodynamics (PKPD). It facilitates data-driven decision-making in pharmacotherapy and drug development by quantifying uncertainty associated with drug behaviour. Pharmacometrics modelling has become an essential tool in the setting of diabetes, especially type 2 diabetes mellitus (T2DM), for comprehending the course of the disease and the consequences of treatment. This method focusses into the pharmacokinetics in various diabetic therapies, dose-response relationships, and the dynamics of insulin and glucose. Pharmacometrics improves clinical decision-making by offering insights into the complex problems linked to diabetes through the integration of many models. Beyond standard evaluation techniques, the use of pharmacometric models increases the statistical power for identifying pharmacological effects. This study emphasises the role that pharmacometrics plays in modelling the course of diabetes and the relationship between insulin and glucose, with the ultimate goal of optimising treatment approaches and enhancing patient outcomes.

Keywords: Pharmacometric; Diabetes; Pharmacokinetics; Pharmacodynamics.

1. Introduction

One of these sophisticated ideas is pharmacometrics, the science of mathematical modelling and simulation. According to Barrett et al., pharmacometrics is "a science of quantitative models in biology, pharmacology, and disease progression that describes the PK/PD behaviours of drugs with respect to their actions including therapeutic and toxic effects."[1].However, pharmacometrics can be understood as the combination of pharmacology, physiology, pathophysiology, mathematics, statistics, and insilico modelling via computer software applications to satisfy the therapeutic and regulatory needs for the development of new drugs and clinical judgement, respectively[2].More effective medication development and more scientific decision-making will result from the worldwide use and exchange of clinical data based on an awareness of ethnic differences or similarities and the suitable application of new techniques[3].Pharmacometrics is a crucial tool for the integration of diverse preclinical and early clinical data via drug exposure, illness models, in clinical drug development, and beyond models to replicate different clinical trial designs and determine the process's future course[4].

2. Relevance of pharmacometrics

2.1. Drug development enhancement

The systematic application of pharmacometrics in drug research and discovery holds promise for significantly advancing medical discoveries and expanding the range of effective therapeutic choices[5]. By creating a model and establishing connections between several basic PK measures and patient characteristics, the specialists are better able

* Corresponding author: Divyaprasath. P

to tailored an RDT dosage schedule based on each patient's unique clinical condition. Compared to other approaches, pharmacometrics analysis provides greater insight into answering questions about the safety, effectiveness, and individualised drug dose schedule of medications in relevant clinical status[6].

2.2. Personalized medicine

Naturally, the mathematical and statistical models used in modelling and simulation approaches are a simplified version of the complex systems being tested. The integration of PK&PD principles is a crucial step in rationalising and effectively carrying out the task of drug development. PK-PD models are applied to explain the relationship between drug dose, concentration, and pharmacologic response, including surrogate markers, efficacy measures, and adverse drug reaction (ADR) events[7].

2.3. Optimising clinical decisions making

The design of clinical trials to be undergone in a clinical drug development process comprises a number of specifications with respect to study population, drug dosage, and assessment by geographically spread multidisciplinary development teams[8].

2.4. Adressing public health needs

Pharmacometrics is a useful and easily implementable idea in LMIC healthcare delivery for creating products that are safe, effective, accessible, and affordable with the lowest possible toxicity and maximum efficacy across a range of patient age groups and clinical statuses[9].



Figure 1 Pharmacometric Process

3. The basics of pharmacometrics

3.1. Pharmacokinetics

In the PK studies, individuals' variability with the administration of therapeutically relevant dosages is examined, and the reasons for variability are further looked at as a tool in dose optimization for specific patients[10][11]. The model that is developed can then be utilised for estimating a patient-specific model that allows for the simulation of various dosage schedules to be done for dose customisation[12]. There are two categories of parameters for the PK model: fixed effect parameters and random effect parameters. The volume of distribution and clearance are represented by a specific value

in fixed effect parameters. The sample mistakes, interindividual variability, and bioanalytical methods are among the random effect parameters[13]. The establishment of such a technique proved PK analysis incredibly useful, not only for designing of novel medications but also for enhancing the treatment of previously approved medications and their repurposed procedures[14].The theory-driven technique known as PK modelling starts with the perception of an organ or tissue. Blood flow, drug concentration in the blood, and partition coefficient all influence how drugs move and behave within the body. The PK model, which has been developed for healthy people, can be adjusted based on the pathophysiology of a certain illness. One set of patients' data can be used to extrapolate the PBPK model to various groups and clinical status[15].Artificial organs may be included in these models as separate compartments, and the medications' changes in pharmacokinetics in these cases may also be intended to allow for tailored drug dose regimens. This type of predicts influence the design of clinical studies to evaluate a medicine for novel applications or help with dose recommendations. Similarly, it is possible to hypothesise and simulate drug interactions using the available pharmacokinetic data[16].

3.2. Pharmacodynamics

The model is a mathematically based schematic description of a complex PD phenomenon that helps to describe and forecast the general behaviour of medications in the body. In the practice of pharmacotherapy and clinical drug development, modelling is an important tool. Population modelling is an intricate process that requires stringent foundational protocols to guarantee accurate data, suitable computing environments, sufficient resources, and efficient communication. It is a time- and money-saving procedure that offers a solid framework for integrating all data gathered on novel medications[17].

4. Applications of pharmacometrics in diabetes

4.1. Disease progression modelling

The most typical form of diabetes, known as type 2 diabetes mellitus (T2DM), typically arises from a larger health issue called metabolic syndrome, which also includes obesity, dyslipidaemia, hypertension, and impaired glucose tolerance[18]. The increase in insulin production resulting from an increase in insulin resistance to maintain normal blood sugar levels is the first step in the progression of diabetes from a healthy state to an overt stage. At a certain point, beta cells are unable to maintain normoglycemia, and when glucose levels rise, beta cell activity is altered. Upon that, the mass of beta cells decreases and the glucose level begins to rise above the prediabetic area. Patients who experience a significant loss in beta-cell mass become ketotic and become insulin-dependent[19]. Few pharmacometrics models have been created that deal with how Type 2 diabetes progresses over time. The models of Mathews et al. (1985)[20] and Bergman et al. (1985)[21]investigated the dynamics of insulin and glucose. These models have been developed on diabetic patients, simulating the dynamics of glucose and insulin by a variety of parameter modifications for various physiological abnormalities.

In order to describe the dynamics of glucose and insulin as quickly as the dynamics of beta-cell mass in healthy persons, Topp et al. created one such model, known as the βIG Model, which is composed of three nonlinear ordinary differential equations. This model accurately evaluated how a single defect or a variety of difficulties affects the system's overall behaviour. According to the model, β-cell mortality occurs when blood glucose levels above 250 mg/dl, exceeding the rate of replication and ultimately bringing the system to a pathological steady state. When blood glucose levels, insulin sensitivity, beta-cell mass, and rates of beta-cell insulin secretion changed, the model responded in a manner akin to that of the glucose regulating system. In addition, the model predicted the existence of three different routes in diabetes: bifurcation, dynamical hyperglycemia, and regulated hyperglycemia. The βIG model offered a structure for formulating experimental procedures aimed at verifying theories concerning β-cell exhaustion and the cause of Type 2 diabetes. Additionally, it offered a means of recognising how β-cell mass, plasma glucose, and plasma insulin behaved in reaction to medical treatments[22].

4.2. Treatment effect of diabetes development

The model was adapted by Ribbing et al. and used for individuals with type 2 diabetes, taking into consideration the impact of both the disease status and treatment on insulin sensitivity and beta-cell mass. Data from three clinical trials with tesaglitazar to treat type 2 diabetes were used to construct the model. According to this concept, impaired beta-cell mass adaptation and a reduction in insulin sensitivity characterised the course of diabetes. Moreover, it has been shown that decreased insulin sensitivity by itself does not cause diabetes because the beta-cell adjusts to the condition and eventually restores the FPG to its usual set point. The consequence of the illness state was utilised to counteract beta-cell adaptation. In comparison to normal participants, all diabetic patients showed deterioration in beta cell mass and insulin sensitivity; insulin sensitivity decreased by an average of 37% to 50% in all subjects, while FPG increased

by 3.1 to 3.9 mmol/L. Tesaglitazar treatment results in enhanced insulin sensitivity, whereas larger dosages almost fully achieved the desired effects on beta-cell mass (OFFSET). Tesaglitazar use has been shown to be strongly correlated with both insulin sensitivity and insulin clearance in the model[23].

5. Conclusion

Diabetes progression over time can be modelled using pharmacometrics, which takes into account a number of variables including insulin-glucose dynamics and pharmacokinetic/pharmacodynamic (PK/PD) connections. By recognising the many complications linked to diabetes, this all-encompassing approach contributes to a better understanding of how these factors interact and impact the course of the disease

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. The Journal of Clinical Pharmacology. 2008 May;48(5):632-49.

[2] Gobburu JV. Pharmacometrics 2020. The Journal of Clinical Pharmacology. 2010 Sep;50(S9):151S-7S.

[3] Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Annals of Pharmacotherapy. 2004 Oct;38(10):1702-6.

[4] Neely M, Bayard D, Desai A, Kovanda L, Edginton A. Pharmacometric modeling and simulation is essential to pediatric clinical pharmacology. The Journal of Clinical Pharmacology. 2018 Oct;58:S73-85.

[5] Pfister M, D'Argenio DZ. The emerging scientific discipline of pharmacometrics. J Clin Pharmacol. 2010 Sep 1;50(9 Suppl):6S.

[6] Usman M, Rasheed H, Pharmacokinetics PB, Creation D. Pharmacometrics and its application in clinical practice. Encyclopedia of Pharmacy Practice and Clinical Pharmacy. 2019 Jan 1:227-38.

[7] Greener M. Drug safety on trial: Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval. EMBO reports. 2005 Mar 1;6(3):202-4.

[8] Gieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. European journal of drug metabolism and pharmacokinetics. 2000 Mar;25:49-58.

[9] Wetherington JD, Pfister M, Banfield C, Stone JA, Krishna R, Allerheiligen S, Grasela DM. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development. The Journal of Clinical Pharmacology. 2010 Sep;50(S9):31S-46S.

[10] Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: modelling and software. Clinical pharmacokinetics. 2012 Aug;51:515-25.

[11] Usman M, Rasheed H, Pharmacokinetics PB, Creation D. Pharmacometrics and its application in clinical practice. Encyclopedia of Pharmacy Practice and Clinical Pharmacy. 2019 Jan 1:227-38.

[12] Allucent, "What is the diference between PBPK and PopPK modeling?," 2018, https://www.allucent.com/resources/blog/what-diference-between-pbpk-and-poppk-modeling.

[13] Stone JA, Banfield C, Pfister M, Tannenbaum S, Allerheiligen S, Wetherington JD, Krishna R, Grasela DM. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. The Journal of Clinical Pharmacology. 2010 Sep;50(S9):20S-30S.

[14] Tsamandouras N, Rostami-Hodjegan A, Aarons L. Combining the 'bottom up'and 'top down'approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. British journal of clinical pharmacology. 2015 Jan;79(1):48-55.

[15] Watt KM, Cohen-Wolkowiez M, Barrett JS, Sevestre M, Zhao P, Brouwer KL, Edginton AN. Physiologically based pharmacokinetic approach to determine dosing on extracorporeal life support: fluconazole in children on ECMO. CPT: pharmacometrics & systems pharmacology. 2018 Oct;7(10):629-37.

[16] Hefti FF. Requirements for a lead compound to become a clinical candidate. BMC neuroscience. 2008 Dec 10;9(Suppl 3):S7.

[17] Owen JS, Fiedler-Kelly J. Introduction to population pharmacokinetic/pharmacodynamic analysis with nonlinear mixed effects models. John Wiley & Sons; 2014 Jun 19.

[18] Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation. 2006 May;23(5):469-80.

[19] Cerf ME. Beta cell dysfunction and insulin resistance. Frontiers in endocrinology. 2013 Mar 27;4:37.

[20] Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocrine reviews. 1985 Jan 1;6(1):45-86.

[21] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. diabetologia. 1985 Jul;28:412-9.

[22] Topp B, Promislow K, Devries G, Miura RM, T FINEGOOD DI. A model of β-cell mass, insulin, and glucose kinetics: pathways to diabetes. Journal of theoretical biology. 2000 Oct 21;206(4):605-19.

[23] Ribbing J, Hamrén B, Svensson MK, Karlsson MO. A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes. The Journal of Clinical Pharmacology. 2010 Aug;50(8):861-72.